Corbus Pharmaceuticals Holdings, Inc.: MPM BioImpact LLC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
MPM BioImpact LLC disclosed a stake exceeding 5% in Corbus Pharmaceuticals Holdings, Inc. via a Schedule 13G filing with the SEC (accession 0001687078-26-000022). The filing signals that the investment firm has crossed the key 5% beneficial ownership threshold, making it a reportable major shareholder in the clinical-stage biotech. The exact share count and percentage were not specified in the headline disclosure. Investors will watch for further detail in the full filing and any subsequent 13G amendments that clarify MPM BioImpact's position size and intent.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
MPM BioImpact LLC, Corbus Pharmaceuticals Holdings, Inc.